Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

SLNO 10.21.2024

Full Press ReleaseSEC FilingsOur SLNO Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.27.2024 - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.17.2024 - 8-K Current report
  • 12.17.2024 - EX-99.1 EX-99.1

REDWOOD CITY, Calif.,Oct. 21, 2024(GLOBE NEWSWIRE) --Soleno Therapeutics, Inc.(“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors,Ernest Mario, Ph.D, at the age of 86 years.Dr. Marioserved as the Soleno’s (formerly Capnia’s) Chairman from 2007 throughAugust 2024.

"On behalf of the Board of Directors and the entire Soleno family, we extend our deepest condolences to Dr. Mario’s family,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Dr. Mario’s decades-long commitment to the development of new treatments for patients with a diverse variety of diseases has few parallels. He was an empathic human and a valuable strategic resource committed to the success of Soleno. We are grateful for his extensive contributions over the years. He will be greatly missed."

Dr. Mario’s career in the pharmaceutical industry began in 1966 as a researcher atStrasenburgh LaboratoriesinRochester, NY. He later held various management positions withinSmithKline and Squibb Corp.and was elected to the Squibb Board in 1984. He joinedGlaxo plcin 1986, and subsequently served as Chief Executive and Deputy Chairman, during which time he oversaw the launch of five major brands as Glaxo became the second-largest pharmaceutical company in the world. In 1993, Ernie joinedAlza Corporationas CEO, where he led what was then one of the largest mergers in pharmaceutical history with Johnson & Johnson. He went on to serve as Chairman and CEO ofReliant Pharmaceuticals, which was acquired by GlaxoSmithKline. In addition, he served on numerous public and private boards over his career.

About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visitwww.soleno.life.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with theSEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

Primary Logo

Source: Soleno Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com